X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs STRIDES PHARMA SCIENCE - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD STRIDES PHARMA SCIENCE BIOCON LTD/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 49.8 51.8 96.2% View Chart
P/BV x 7.3 1.1 643.7% View Chart
Dividend Yield % 0.2 0.4 37.0%  

Financials

 BIOCON LTD   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    BIOCON LTD
Mar-18
STRIDES PHARMA SCIENCE
Mar-18
BIOCON LTD/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs1,1881,147 103.6%   
Low Rs305642 47.5%   
Sales per share (Unadj.) Rs68.7317.2 21.7%  
Earnings per share (Unadj.) Rs7.67.8 96.3%  
Cash flow per share (Unadj.) Rs14.025.1 55.8%  
Dividends per share (Unadj.) Rs1.002.00 50.0%  
Dividend yield (eoy) %0.10.2 59.9%  
Book value per share (Unadj.) Rs86.3274.3 31.5%  
Shares outstanding (eoy) m600.0089.50 670.4%   
Bonus/Rights/Conversions ISESOP-  
Price / Sales ratio x10.92.8 385.3%   
Avg P/E ratio x98.9114.0 86.7%  
P/CF ratio (eoy) x53.435.7 149.7%  
Price / Book Value ratio x8.63.3 265.1%  
Dividend payout %13.225.5 51.9%   
Avg Mkt Cap Rs m447,90080,058 559.5%   
No. of employees `0006.12.5 245.3%   
Total wages/salary Rs m9,3114,341 214.5%   
Avg. sales/employee Rs Th6,705.811,325.8 59.2%   
Avg. wages/employee Rs Th1,514.21,731.4 87.5%   
Avg. net profit/employee Rs Th736.9280.1 263.1%   
INCOME DATA
Net Sales Rs m41,23428,394 145.2%  
Other income Rs m2,062941 219.2%   
Total revenues Rs m43,29629,334 147.6%   
Gross profit Rs m8,2913,965 209.1%  
Depreciation Rs m3,8511,540 250.0%   
Interest Rs m6151,962 31.3%   
Profit before tax Rs m5,8871,403 419.5%   
Minority Interest Rs m2130-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m1,56997 1,612.5%   
Profit after tax Rs m4,531702 645.3%  
Gross profit margin %20.114.0 144.0%  
Effective tax rate %26.76.9 384.4%   
Net profit margin %11.02.5 444.4%  
BALANCE SHEET DATA
Current assets Rs m41,48624,836 167.0%   
Current liabilities Rs m21,41318,993 112.7%   
Net working cap to sales %48.720.6 236.6%  
Current ratio x1.91.3 148.2%  
Inventory Days Days6471 90.1%  
Debtors Days Days94113 83.0%  
Net fixed assets Rs m50,66134,289 147.7%   
Share capital Rs m3,000895 335.2%   
"Free" reserves Rs m48,80823,651 206.4%   
Net worth Rs m51,80824,546 211.1%   
Long term debt Rs m17,89815,513 115.4%   
Total assets Rs m99,89765,437 152.7%  
Interest coverage x10.61.7 616.4%   
Debt to equity ratio x0.30.6 54.7%  
Sales to assets ratio x0.40.4 95.1%   
Return on assets %5.24.1 126.5%  
Return on equity %8.72.9 305.8%  
Return on capital %9.66.9 139.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,05815,697 76.8%   
Fx outflow Rs m7,348735 999.2%   
Net fx Rs m4,71014,962 31.5%   
CASH FLOW
From Operations Rs m6,6211,871 353.9%  
From Investments Rs m-6,8405,826 -117.4%  
From Financial Activity Rs m-2,397-10,157 23.6%  
Net Cashflow Rs m-2,612-2,615 99.9%  

Share Holding

Indian Promoters % 40.4 27.7 145.8%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 37.8 22.2%  
FIIs % 10.7 8.6 124.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 25.9 76.8%  
Shareholders   109,995 56,241 195.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   PANACEA BIOTECH  DIVIS LABORATORIES  FULFORD INDIA  NATCO PHARMA  AJANTA PHARMA  

Compare BIOCON LTD With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 345 Points Lower; Auto and Telecom Stocks Witness Selling(Closing)

Share markets in India witnessed most of the selling pressure during closing hours and ended their trading session on a negative note.

Related Views on News

BIOCON LTD Announces Quarterly Results (2QFY19); Net Profit Up 501.9% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, BIOCON LTD has posted a net profit of Rs 4 bn (up 501.9% YoY). Sales on the other hand came in at Rs 13 bn (up 36.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY19); Net Profit Down 72.2% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 54 m (down 72.2% YoY). Sales on the other hand came in at Rs 7 bn (down 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

3 Big Money Makers to Round Out Your 2018 Portfolio(Profit Hunter)

Oct 31, 2018

The market is offering many strong opportunities in the small cap space right now. Don't miss out. This is the time to get rich.

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Nov 12, 2018 (Close)

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

BIOCON LTD 8-QTR ANALYSIS

COMPARE BIOCON LTD WITH

MARKET STATS